← All tickers

Is BCRX Worth Buying in 2026?

BioCryst Pharmaceuticals Inc

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-06-14

Here’s whether BioCryst Pharmaceuticals Inc (BCRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: trading above the 200-day MA (long-term uptrend intact); RSI 57 — healthy momentum range. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.49% over 10 days); weak 1-year return of -16.4%; 3-month momentum negative (-6.5%). Currently 18.2% off its 52-week high. Score: -1/7.

Ready to act on this? 📈 Trade on Webull

BCRX is holding above its long-term 200-day MA ($7.92) but has slipped below the 50-day MA ($8.95), pointing to short-term weakness in an otherwise intact trend. An RSI of 57.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -16.4% compares to +22.9% for SPY (trailed the market by 39.2%).

$10,000 invested 1 year ago → $8,365 today
vs. S&P 500 (SPY) — same period trailed market by 39.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($7.92)
✗Above 50-day MA ($8.95)
✓RSI(14) neutral zone (30–70) — currently 57.5
✗Positive return (-16.4%)
!Within 10% of period high (−18.2%)
Period Range $8.70
$6.00 $10.64
RSI (14) 57.5
0 · OversoldOverbought · 100

Key Metrics

Price$8.70
Period Return-16.4%
Period High$10.64
Period Low$6.00
Drawdown−18.2%
MA-50$8.95
MA-200$7.92
RSI (14)57.5
Avg Volume (30d)4.6M
vs. SPYtrailed by 39.2%
Return Rank#836 of 1246

Trade BCRX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers